Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06065540
Ignite Creation Date: 2024-05-06 @ 7:36 PM
Last Modification Date: 2024-10-26 @ 3:10 PM
Study NCT ID: NCT06065540
Protocol Section: NCT06065540
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Research Study to See How Well CagriSema Compared to Semaglutide Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Official Title: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide CagriSema sc in Doses 2424 mg and 1010 mg Once Weekly Versus Semaglutide 24 mg and 10 mg Cagrilintide 24 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Acronym: REIMAGINE 2
Organization: Novo Nordisk AS
Organization Class: INDUSTRY
Organization Study ID: NN9388-4896
Secondary IDs
Secondary ID Type Domain Link
U1111-1283-0427 OTHER None None
2022-502678-18 EUDRACT_NUMBER World Health Organization WHO None
Start Status Module Data
Status Verified Date: 2024-09
Overall Status: ACTIVE_NOT_RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Novo Nordisk AS
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Novo Nordisk AS
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload